The European Commission approved AbbVie’s Rinvoq (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 and older. This decision establishes the oral JAK inhibitor as the first and only systemic medication for this indication in the European Union.
The treatment addresses a significant unmet need for patients living with this chronic autoimmune disease. Non-segmental vitiligo is the most common form of the condition, characterized by skin pigment loss in patches.
Approval followed positive results from the Phase 3 Viti-Up clinical program. Rinvoq achieved statistically significant improvements in total body and facial repigmentation compared to a placebo after 48 weeks.